Mission Bio, the single-cell multi-omics leader, today released data showing that its Targeted Single-Cell DNA+RNA Assay ...
Stuart Orkin and Swee Lay Thein shared a Breakthrough Prize in Life Sciences for their research on genetic causes of sickle ...
CRISPR gene therapy increases haemoglobin and fetal haemoglobin in sickle cell disease, reducing vaso occlusive events in ...
A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. The technology has largely been tested in cells ...
The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...
A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...
A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...
Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...
Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one of a select few worldwide ...
Zacks Investment Research on MSN
CRISPR Therapeutics' Q1 loss wider than expected, sales miss estimates
CRISPR Therapeutics CRSP reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results